Bevacizumab for glioblastoma multiforme after traumatic subarachnoid hemorrhage

Rimas V. Lukas*, Fernando Goldenberg, Martin K. Nicholas

*Corresponding author for this work

Research output: Contribution to journalArticle

1 Scopus citations


We present a patient with a glioblastoma multiforme treated with bevacizumab who suffered a traumatic subarachnoid hemorrhage (SAH). Trascranial doppler revealed no evidence of vasoconstriction, which has been previously described in a bevacizumab-treated patient. Bevacizumab was resumed five weeks after the SAH without recurrence of bleeding or vasoconstriction. To our knowledge this is the first report of resumption of bevacizumab after SAH.

Original languageEnglish (US)
Pages (from-to)1310-1311
Number of pages2
JournalJournal of Clinical Neuroscience
Issue number9
StatePublished - Sep 1 2012


  • Bevacizumab
  • Brain tumor
  • Glioblastoma
  • Subarachnoid hemorrhage
  • Transcranial dopplers

ASJC Scopus subject areas

  • Surgery
  • Neurology
  • Clinical Neurology
  • Physiology (medical)

Fingerprint Dive into the research topics of 'Bevacizumab for glioblastoma multiforme after traumatic subarachnoid hemorrhage'. Together they form a unique fingerprint.

  • Cite this